Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier
Aldo Torre,1,2 Jacqueline Córdova-Gallardo,3 Alberto C Frati Munari4 1Guest Research, Metabolic Unit Department, Instituto Nacional de Ciencias Médicas Y Nutrición “Salvador Zubirán”, México City, Mexico; 2Guest Research, Liver Unit Department, Hospital General de México, México City, Mexico; 3Hepat...
Main Authors: | Torre A, Córdova-Gallardo J, Frati Munari AC |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-10-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/rifaximin-alfa-and-liver-diseases-more-than-a-treatment-for-encephalop-peer-reviewed-fulltext-article-TCRM |
Similar Items
-
Comparative Analysis of the Efficacy of Different Regimens of 12 Months Rifaximin-Alfa Therapy in Patients with Liver Cirrhosis and Minimal Hepatic Encephalopathy
by: Igor G. Bakulin, et al.
Published: (2023-10-01) -
Role of Rifaximin in Prevention of Recurrent Hepatic Encephalopathy in Chronic Liver Disease
by: Sahar Farzand, et al.
Published: (2020-12-01) -
Preventive and therapeutic effects of rifaximin on hepatic encephalopathy with differential application dosages and strategies: a network meta-analysis
by: Guihua Fang, et al.
Published: (2024-03-01) -
Rifaximin alone vs combination with norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis with hepatic encephalopathy: randomized controlled trial
by: Tarana Gupta, et al.
Published: (2024-09-01) -
Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients
by: Kosuke Kaji, et al.
Published: (2020-03-01)